Ensayos clínicos

8.676 ensayos encontrados

ReclutandoClinicalTrials.gov

An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line

OBSERVATIONALInicio: 27 de nov de 2023ID: NCT06117891

ReclutandoClinicalTrials.gov

Maternal Characteristics Associated With Child Growth and Adiposity. Search for Nutrigenomic Biomarkers in Peripheral Blood

OBSERVATIONALInicio: 2 de may de 2019ID: NCT05798676

ReclutandoFase 3ClinicalTrials.gov

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

INTERVENTIONALInicio: 7 de sept de 2023ID: NCT06051617

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

INTERVENTIONALInicio: 15 de feb de 2023ID: NCT05702034

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

INTERVENTIONALInicio: 27 de feb de 2023ID: NCT05723198

ReclutandoFase 2ClinicalTrials.gov

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)

INTERVENTIONALInicio: 26 de mar de 2026ID: NCT07293351

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

INTERVENTIONALInicio: 27 de sept de 2022ID: NCT05503264

ReclutandoFase 3ClinicalTrials.gov

Phase III Randomized,Multicenter Non-inferiority Study to Evaluate the Efficacy and Safety of Shorter Benznidazole Regimens Compared to the Standard Regimen to Treat Adult Patients With Chronic Chagas Disease

INTERVENTIONALInicio: 28 de jul de 2021ID: NCT04897516

ReclutandoClinicalTrials.gov

My Journey - Prospective Cohort of Perioperative Results

OBSERVATIONALInicio: 1 de ene de 2023ID: NCT05755230

ReclutandoFase 3ClinicalTrials.gov

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

INTERVENTIONALInicio: 5 de oct de 2023ID: NCT05952557

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

INTERVENTIONALInicio: 9 de abr de 2025ID: NCT06790693

ReclutandoFase 3ClinicalTrials.gov

Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy - Multicenter Double Blind Randomized and Controlled Trial

INTERVENTIONALInicio: 18 de nov de 2024ID: NCT03676439

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

INTERVENTIONALInicio: 21 de oct de 2024ID: NCT06623422

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

INTERVENTIONALInicio: 4 de jun de 2025ID: NCT07000357

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

INTERVENTIONALInicio: 6 de feb de 2025ID: NCT06834360

ReclutandoClinicalTrials.gov

Prospective Registry of Patients With Systemic Lupus Erythematosus of the Argentinian Society of Rheumatology

OBSERVATIONALInicio: 1 de abr de 2022ID: NCT05470569

ReclutandoClinicalTrials.gov

Baseline Ventilatory Parameters in Patients With Acute Neurological Injury

OBSERVATIONALInicio: 1 de may de 2024ID: NCT06192342

ReclutandoFase 2ClinicalTrials.gov

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL

INTERVENTIONALInicio: 4 de ene de 2021ID: NCT04521231

ReclutandoClinicalTrials.gov

A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer

OBSERVATIONALInicio: 4 de mar de 2025ID: NCT06767462

ReclutandoClinicalTrials.gov

Clinical Trial in Hypertensive Patients Comparing Two Cardiorespiratory Exercise Protocols, Low-volume Sprint Interval Training (SIT) Versus Moderate-intensity Continuous Training (MICT), to Evaluate Decreases in Ambulatory Blood Pressure and Other Clinical Variables.

INTERVENTIONALInicio: 29 de abr de 2025ID: NCT07229196